Perspective Therapeutics (NYSEAMERICAN:CATX) Stock: Insider Johan Spoor Buys 47,000 Shares

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) CEO Johan Spoor purchased 47,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 11th. The stock was acquired at an average price of $0.81 per share, with a total value of $38,070.00. Following the purchase, the chief executive officer owned 106,383 shares in the company, valued at $86,170.23. This represents a 79.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Perspective Therapeutics Price Performance

NYSEAMERICAN CATX traded up $0.10 during trading hours on Friday, reaching $0.94. The company’s stock had a trading volume of 3,183,208 shares, compared to its average volume of 4,328,272. Perspective Therapeutics, Inc. has a 1-year low of $0.78 and a 1-year high of $6.16. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.61 and a current ratio of 5.18. The company’s 50-day moving average is $2.11 and its two-hundred day moving average is $3.44.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.06 million. Perspective Therapeutics had a negative return on equity of 42.25% and a negative net margin of 55,866.82%. On average, sell-side analysts anticipate that Perspective Therapeutics, Inc. will post -1.01 EPS for the current year.

Hedge Funds Weigh In On Perspective Therapeutics

A number of hedge funds have recently made changes to their positions in CATX. Provenance Wealth Advisors LLC purchased a new position in shares of Perspective Therapeutics in the third quarter valued at approximately $44,000. Auctus Advisors LLC boosted its stake in shares of Perspective Therapeutics by 83.6% in the third quarter. Auctus Advisors LLC now owns 37,359 shares of the company’s stock worth $103,000 after acquiring an additional 17,015 shares during the last quarter. Russell Investments Group Ltd. increased its position in shares of Perspective Therapeutics by 53.1% during the third quarter. Russell Investments Group Ltd. now owns 61,012 shares of the company’s stock worth $168,000 after purchasing an additional 21,150 shares in the last quarter. Taylor & Morgan Wealth Management LLC increased its position in shares of Perspective Therapeutics by 127.6% during the second quarter. Taylor & Morgan Wealth Management LLC now owns 66,000 shares of the company’s stock worth $225,000 after purchasing an additional 37,000 shares in the last quarter. Finally, Quantinno Capital Management LP purchased a new stake in shares of Perspective Therapeutics during the first quarter worth approximately $273,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Trending Headlines about Perspective Therapeutics

Investors following CATX have been watching these headlines:

• Positive Sentiment: CEO Johan Spoor bought 47,000 shares at an average price of $0.81, increasing his holdings by 79%. Insider Markus Puhlmann also bought 41,000 shares across two transactions at average prices of $0.83 and $0.84. These open-market purchases may signal insiders’ confidence in the company. Insider purchase report
• Positive Sentiment: BMO Capital gave CATX a Buy rating, adding a bullish analyst view. BMO Capital rating
• Neutral Sentiment: Brookline Capital Markets made slightly different revisions to its earnings forecasts: it raised its Q4 2026 estimate to a loss of $0.25 per share from $0.26, but lowered its full-year estimate to a loss of $1.00 from $0.99. Perspective Therapeutics analyst estimates

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. BMO Capital Markets reissued an “outperform” rating on shares of Perspective Therapeutics in a research note on Friday, October 30th. William Blair assumed coverage on shares of Perspective Therapeutics in a report on Friday, September 18th. They issued an “outperform” rating for the company. Wedbush restated an “outperform” rating and set a $7.00 price objective (down from $9.00) on shares of Perspective Therapeutics in a research report on Tuesday, November 10th. Bank of America decreased their price objective on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating on the stock in a report on Friday, August 14th. Finally, Piper Sandler dropped their target price on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. Nine investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.10.

About Perspective Therapeutics

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.